AstraZeneca’s Baxdrostat Shows Promising Results in Resistant Hypertension Trial

AstraZeneca announced positive Phase III BaxHTN trial results for baxdrostat, a selective aldosterone synthase inhibitor, showing a significant reduction in seated systolic blood pressure (SBP) after 12 weeks compared to placebo. The study involved 796 patients with uncontrolled or resistant hypertension, all on at least two antihypertensive drugs, and met all primary and secondary endpoints.

Participants received either 1mg, 2mg, or placebo once daily during a 12-week double-blind phase. A randomised withdrawal period (week 24–32) further confirmed the durability of baxdrostat’s efficacy. Over 300 subjects on the 2mg dose were re-randomised to continue treatment or switch to placebo, with SBP changes measured.

Additional outcomes included improvements in diastolic BP, more patients reaching SBP <130 mmHg, and a favourable safety profile. Results will be presented at the ESC Congress 2025. Baxdrostat entered AstraZeneca’s portfolio following the CinCor Pharma acquisition in February 2023.

15-07-2025